Effects of spironolactone on cerebral vessel structure in rats with sustained hypertension.

BACKGROUND Spironolactone prevents eutrophic middle cerebral artery (MCA) remodeling in young stroke-prone spontaneously hypertensive rats (SHRSP). Clinically, it is more relevant to identify treatments that improve vessel structure after hypertension and remodeling has developed. We hypothesized that spironolactone would increase the MCA lumen diameter and reduce the wall/lumen ratio in SHRSP treated from 12 to 18 weeks of age. METHODS Twelve-week-old male SHRSP were treated with spironolactone (SHRSP + spir: 25 mg/kg/day) for 6 weeks and were compared at 18 weeks to age matched untreated SHRSP and Wistar Kyoto (WKY) rats. MCA structure was assessed by pressure myography. The WKY rats were included to provide an indication of the magnitude of the hypertensive MCA remodeling. RESULTS Spironolactone had no effect on blood pressure as measured by telemetry. MCA myogenic tone was enhanced in the SHRSP + spir. Spironolactone increased the MCA lumen diameter (SHRSP: 223.3 ± 9.7 µm, SHRSP + spir: 283.7 ± 10.1 µm, WKY: 319.5 ± 8.8 µm, analysis of variance (ANOVA) P < 0.05) and reduced the wall/lumen ratio (SHRSP: 0.107 ± 0.007, SHRSP + spir: 0.078 ± 0.006, WKY: 0.047 ± 0.002, ANOVA P < 0.05). Vessel wall stiffness was unchanged by spironolactone. Collagen 1 and 4 mRNA expression was increased in cerebral vessels from SHRSP compared to WKY rats; collagen 1 was reduced by spironolactone. Western blot analysis showed that active matrix metalloproteinase (MMP)-13 expression was increased by spironolactone treatment. The expression of intercellular adhesion molecule 1 (ICAM-1), a marker of inflammation, was increased in SHRSP and reduced by spironolactone. CONCLUSIONS These studies provide evidence that chronic mineralocorticoid receptor (MR) antagonism improves cerebral vessel structure after remodeling has developed in a model of human essential hypertension.

[1]  A. Dorrance,et al.  Mineralocorticoid Receptor Activation Causes Cerebral Vessel Remodeling and Exacerbates the Damage Caused by Cerebral Ischemia , 2006, Hypertension.

[2]  D. Heistad,et al.  Remodeling of Cerebral Arterioles in Chronic Hypertension , 1989, Hypertension.

[3]  A. Dominiczak,et al.  Myogenic and structural properties of cerebral arteries from the stroke-prone spontaneously hypertensive rat. , 2003, American journal of physiology. Heart and circulatory physiology.

[4]  G. Osol,et al.  Effect of antihypertensive treatment on myogenic properties of brain arteries from the stroke-prone rat. , 1986, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[5]  A. Dorrance,et al.  Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats. , 2007, Microvascular research.

[6]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[7]  D. Heistad,et al.  Effects of Antihypertensive Therapy on Mechanics of Cerebral Arterioles in Rats , 1991, Hypertension.

[8]  N. Chesler,et al.  Effects of ischemia and myogenic activity on active and passive mechanical properties of rat cerebral arteries. , 2002, American journal of physiology. Heart and circulatory physiology.

[9]  M. Safar,et al.  Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[10]  J. Marrs.  Spironolactone Management of Resistant Hypertension , 2010, The Annals of pharmacotherapy.

[11]  A. Dorrance,et al.  Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[12]  U. Ikeda.  Inflammation and coronary artery disease. , 2003, Current vascular pharmacology.

[13]  M. Young,et al.  Corticosteroid receptors, macrophages and cardiovascular disease. , 2009, Journal of molecular endocrinology.

[14]  A. Nagaoka,et al.  Pathogenesis and prevention of stroke in spontaneously hypertensive rats. , 1975, Clinical science and molecular medicine. Supplement.

[15]  M. Safar,et al.  Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. , 2001, Journal of the American College of Cardiology.

[16]  S. Whitebread,et al.  Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. , 1987, The Journal of pharmacology and experimental therapeutics.

[17]  P. Milliez,et al.  Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. , 2005, Journal of the American College of Cardiology.

[18]  J. Funder.  Mineralocorticoid Receptors: Distribution and Activation , 2005, Heart Failure Reviews.

[19]  D. Harder,et al.  Enhanced myogenic depolarization in hypertensive cerebral arterial muscle. , 1985, Circulation research.

[20]  E. Heerkens,et al.  Middle cerebral artery structure and distensibility during developing and established phases of hypertension in the spontaneously hypertensive rat , 2006, Journal of hypertension.

[21]  N. Stergiopulos,et al.  Effects of reduced cyclic stretch on vascular smooth muscle cell function of pig carotids perfused ex vivo. , 2008, American journal of hypertension.

[22]  A. la Sala,et al.  Functional Mineralocorticoid Receptors in Human Vascular Endothelial Cells Regulate Intercellular Adhesion Molecule-1 Expression and Promote Leukocyte Adhesion , 2008, Circulation research.

[23]  P. Chander,et al.  Effect of Aldosterone and MR Blockade on the Brain and the Kidney , 2005, Heart Failure Reviews.

[24]  J. Pollock,et al.  Renal endothelin in chronic angiotensin II hypertension. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[25]  J. Connell,et al.  Is altered adrenal steroid biosynthesis a key intermediate phenotype in hypertension? , 2003, Hypertension.

[26]  J. Atkinson,et al.  Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive rats , 2005, Journal of hypertension.

[27]  G. Baumbach,et al.  Mechanics of large and small cerebral arteries in chronic hypertension. , 1994, The American journal of physiology.

[28]  A. Dorrance,et al.  Diet-induced obesity causes cerebral vessel remodeling and increases the damage caused by ischemic stroke. , 2009, Microvascular research.

[29]  A. Dorrance,et al.  Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[30]  A. Nishiyama,et al.  Possible Involvement of Rho-Kinase in Aldosterone-Induced Vascular Smooth Muscle Cell Remodeling , 2008, Hypertension Research.

[31]  E. Schiffrin,et al.  From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. , 2004, American journal of physiology. Heart and circulatory physiology.

[32]  E. Schiffrin,et al.  Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. , 2000, Circulation.

[33]  E. Schiffrin.  Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. , 2004, American journal of hypertension.

[34]  G. Baumbach,et al.  Mechanics and composition of cerebral arterioles in renal and spontaneously hypertensive rats. , 1993, Hypertension.

[35]  J. Conn,et al.  CLINICAL CHARACTERISTICS OF PRIMARY ALDOSTERONISM FROM AN ANALYSIS OF 145 CASES. , 1964, American journal of surgery.

[36]  C. Stier,et al.  Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. , 1998, Hypertension.

[37]  U. Ikeda,et al.  Inflammatory cytokines and cardiovascular disease. , 2003, Current drug targets. Inflammation and allergy.

[38]  A. Dorrance,et al.  Is the mineralocorticoid receptor a potential target for stroke prevention? , 2008, Clinical science.

[39]  M. Mulvany,et al.  The myogenic response: established facts and attractive hypotheses. , 1999, Clinical science.

[40]  T Fahey,et al.  Interventions used to improve control of blood pressure in patients with hypertension. , 2006, The Cochrane database of systematic reviews.

[41]  G. McMahon,et al.  Glucocorticoid-Remediable Aldosteronism , 2004, Cardiology in review.

[42]  G. Osol,et al.  Biomechanics and Mechanotransduction in Cells and Tissues Effects of Rho kinase inhibition on cerebral artery myogenic tone and reactivity , 2005 .

[43]  A. Dominiczak,et al.  Sex-specific differences in cerebral arterial myogenic tone in hypertensive and normotensive rats. , 2006, American journal of physiology. Heart and circulatory physiology.

[44]  D. Heistad,et al.  Impaired dilatation of cerebral arterioles in chronic hypertension. , 1990, Blood vessels.

[45]  P. Coyle.  Dorsal cerebral collaterals of stroke‐prone spontaneously hypertensive rats (SHRSP) and Wistar Kyoto rats (WKY) , 1987, The Anatomical record.

[46]  P. Coyle,et al.  Differential outcome to middle cerebral artery occlusion in spontaneously hypertensive stroke‐prone rats (SHRSP) and Wistar Kyoto (WKY) rats. , 1983, Stroke.

[47]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[48]  J. Chillon,et al.  Effects of an Angiotensin-Converting Enzyme Inhibitor and a β-Blocker on Cerebral Arterioles in Rats , 1999 .